Wide Ranks

CSCI

COSCIENS Biopharma Inc.

3.09

Top Statistics
Market Cap 9 M Forward PE 0.0000 Revenue Growth 62266.70 %
Current Ratio 3.46 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.3420 Enterprise / Revenue -1.82 Price To Sales Trailing12 Months 2.00
Profitability
Profit Margins 0.00 % Operating Margins -258.36 %
Balance Sheet
Total Cash 19 M Total Cash Per Share 6.44 Total Debt 1 M
Total Debt To Equity 8.07 Current Ratio 3.46 Book Value Per Share 6.44
All Measures
Short Ratio 27.00 % Message Board Id finmb_416430 Shares Short Prior Month 6774
Return On Equity -1.00 City Toronto Uuid ee063970-8fec-3fda-9e0f-33dd7732c450
Previous Close 3.07 First Trade Date Epoch Utc 957 M Book Value 6.44
Total Debt 1 M Volume 4510 Price To Book 0.4796
Last Split Date 1 B Fifty Two Week Low 2.62 Total Cash Per Share 6.44
Total Revenue 4 M Shares Short Previous Month Date 1 B Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -258.36 % Net Income To Common -23209000
Ask 4.30 Implied Shares Outstanding 3 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 8110 Average Volume10days 8110
Total Cash 19 M Next Fiscal Year End 1 B Revenue Per Share 2.98
Held Percent Insiders 0.0130 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 3.07 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.57 Open 2.95
Free Cashflow -17042250 State ON Dividend Yield 0.00 %
Return On Assets -0.3743 Time Zone Short Name EST Trailing Eps -4.46
Day Low 2.95 Address1 222 Bay Street Shares Outstanding 3 M
Price Hint 4 Target High Price 0.0000 Website https://www.cosciensbio.com
52 Week Change -0.6098 Average Volume 5862 Recommendation Key none
Forward Eps 0.0000 Compensation As Of Epoch Date 1 B Quick Ratio 269.50 %
Last Split Factor 1:4 Regular Market Day High 3.09 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 8.07 Fifty Two Week High 11.10
Day High 3.09 Shares Short 5116 Regular Market Open 2.95
Industry Key biotechnology Bid 3.28 Earnings Growth 0.00 %
Enterprise To Revenue -1.82 Revenue Growth 62266.70 % Shares Percent Shares Out 0.0004
Operating Cashflow -27190000 Currency USD Time Zone Full Name America/New_York
Market Cap 9 M Is_nasdaq_100 False Zip M5K 1E7
Quote Type EQUITY Industry Biotechnology Long Name COSCIENS Biopharma Inc.
Regular Market Day Low 2.95 Held Percent Institutions 0.0636 Current Price 3.09
Address2 Suite 3000 PO Box 53 Enterprise To Ebitda 0.3420 Financial Currency USD
Current Ratio 3.46 Gross Margins 86.18 % Industry Disp Biotechnology
Country Canada Float Shares 2 M Two Hundred Day Average 5.97
Ir Website http://www.aezsinc.com/en/page.php?p=50 Enterprise Value -8782906 Price To Sales Trailing12 Months 2.00
Forward PE 0.0000 Regular Market Volume 4510 Ebitda -25681000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.

Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.

The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease.

In addition, it has a license agreement with Consilient Health Ltd.

and NK MEDITECH Ltd.

for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.

The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.

COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.